Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1992 May;68(799):371–375. doi: 10.1136/pgmj.68.799.371

Lipid and lipoprotein metabolism in familial combined hyperlipidaemia during treatment of sporadic phaeochromocytoma: a case study.

P H Winocour 1, T Masud 1, F Clark 1, B G Cooper 1, M F Laker 1, K G Alberti 1
PMCID: PMC2399417  PMID: 1630985

Abstract

Lipid metabolism was evaluated during management of phaeochromocytoma in a 41 year old non-obese post-menopausal women with familial combined hyperlipidaemia. The main effect of the excess catecholamine secretion on lipid metabolism was increased lipolytic activity, lower serum triglyceride and increased HDL cholesterol concentrations, compared with findings following removal of the tumour. Before removal of the tumour, the use of beta blockers alone led to marked deterioration of the hyperlipidaemic state, and combined alpha and beta blockade additionally led to a marked reduction in fat oxidation and lipoprotein lipase activity. Overactivity of the adrenergic system leads to changes in lipid metabolism in phaeochromocytoma. Treatment of the phaeochromocytoma may lead to worsening of hyperlipidaemia pre-existing in such individuals.

Full text

PDF
371

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Day J. L., Metcalfe J., Simpson C. N. Adrenergic mechanisms in control of plasma lipid concentrations. Br Med J (Clin Res Ed) 1982 Apr 17;284(6323):1145–1148. doi: 10.1136/bmj.284.6323.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Durrington P. N., Brownlee W. C., Large D. M. Short-term effects of beta-adrenoceptor blocking drugs with and without cardioselectivity and intrinsic sympathomimetic activity on lipoprotein metabolism in hypertriglyceridaemic patients and in normal men. Clin Sci (Lond) 1985 Dec;69(6):713–719. doi: 10.1042/cs0690713. [DOI] [PubMed] [Google Scholar]
  3. Frayn K. N. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol Respir Environ Exerc Physiol. 1983 Aug;55(2):628–634. doi: 10.1152/jappl.1983.55.2.628. [DOI] [PubMed] [Google Scholar]
  4. Kather H., Säuberlich P. Comparison of in vitro and in vivo effects of prazosin on lipid metabolism. Am J Med. 1984 Feb 27;76(2A):89–93. doi: 10.1016/0002-9343(84)90962-8. [DOI] [PubMed] [Google Scholar]
  5. Krentz A. J., Hale P. J., Horrocks P. M., Heslop K. E., Johnston D. G., Wright A. D., Nattrass M. Metabolic effects of pharmacological adrenergic blockade in phaeochromocytoma. Clin Endocrinol (Oxf) 1991 Feb;34(2):139–145. doi: 10.1111/j.1365-2265.1991.tb00284.x. [DOI] [PubMed] [Google Scholar]
  6. Lenders J. W., Sluiter H. E., Thien T., Willemsen J. Treatment of a phaeochromocytoma of the urinary bladder with nifedipine. Br Med J (Clin Res Ed) 1985 Jun 1;290(6482):1624–1625. doi: 10.1136/bmj.290.6482.1624-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Miller N. E. Effects of adrenoceptor-blocking drugs on plasma lipoprotein concentrations. Am J Cardiol. 1987 Sep 18;60(9):17E–23E. doi: 10.1016/0002-9149(87)90537-6. [DOI] [PubMed] [Google Scholar]
  8. Rogers M. P., Barnett D., Robinson D. S. Effects of clofibrate treatment on plasma triglyceride concentration, plasma post-heparin clearing factor lipase (lipoprotein lipase) activity and serum clearing factor lipase activating ability in maturity-onset diabetes. Atherosclerosis. 1976 Sep;24(3):565–573. doi: 10.1016/0021-9150(76)90148-9. [DOI] [PubMed] [Google Scholar]
  9. Ross E. J., Griffith D. N. The clinical presentation of phaeochromocytoma. Q J Med. 1989 Jun;71(266):485–496. [PubMed] [Google Scholar]
  10. Rössner S. Studies on an intravenous fat tolerance test. Methodological, experimental and clinical experiences with Intralipid. Acta Med Scand Suppl. 1974;564:1–24. [PubMed] [Google Scholar]
  11. Schauer I., Schauer U., Rühling K., Thielmann K. The effect of propranolol treatment on total cholesterol, HDL cholesterol, triglycerides. Postheparin lipolytic activity and lecithin:cholesterol acyltransferase in hypertensive individuals. Artery. 1980;8(2):146–150. [PubMed] [Google Scholar]
  12. Serfas D., Shoback D. M., Lorell B. H. Phaeochromocytoma and hypertrophic cardiomyopathy: apparent suppression of symptoms and noradrenaline secretion by calcium-channel blockade. Lancet. 1983 Sep 24;2(8352):711–713. doi: 10.1016/s0140-6736(83)92250-x. [DOI] [PubMed] [Google Scholar]
  13. Sheps S. G., Jiang N. S., Klee G. G., van Heerden J. A. Recent developments in the diagnosis and treatment of pheochromocytoma. Mayo Clin Proc. 1990 Jan;65(1):88–95. doi: 10.1016/s0025-6196(12)62113-2. [DOI] [PubMed] [Google Scholar]
  14. Turnbull D. M., Johnston D. G., Alberti K. G., Hall R. Hormonal and metabolic studies in a patient with a pheochromocytoma. J Clin Endocrinol Metab. 1980 Oct;51(4):930–933. doi: 10.1210/jcem-51-4-930. [DOI] [PubMed] [Google Scholar]
  15. Vance J. E., Buchanan K. D., O'Hara D., Williams R. H., Porte D., Jr Insulin and glucagon responses in subjects with pheochromocytoma: effect of alpha adrenergic blockade. J Clin Endocrinol Metab. 1969 Jul;29(7):911–916. doi: 10.1210/jcem-29-7-911. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES